Indobufen <i>versus</i> aspirin in dual antiplatelet therapy: a retrospective study of effects on serum uric acid levels and gout attacks in patients post-coronary stenting

Objective This retrospective study compared the effects of indobufen versus aspirin, each combined with clopidogrel, on serum uric acid (SUA) levels and gout attacks in patients undergoing coronary stenting. Methods Among 213 enrolled patients, 156 were included after propensity score matching and assigned to either the indobufen plus clopidogrel group ( n = 78) or the aspirin plus clopidogrel group ( n = 78). SUA levels were measured at baseline and at the 1-month, 6-month, and 1-year follow-ups. Gout attacks and major cardiovascular events were recorded throughout the study. Results Baseline characteristics were comparable. The indobufen group showed significant reductions in SUA levels at all follow-ups (all, P &lt; 0.001), whereas levels in the aspirin group remained stable. Although the initial gout attack rates at baseline were similar between groups, the probability of recurrence during follow-up was lower in the indobufen group. Cardiovascular safety profiles were comparable between groups. Conclusion Indobufen plus clopidogrel significantly reduced SUA levels and showed a favorable trend in reducing gout recurrences without compromising cardiovascular safety.